Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2013

01-08-2013 | Review

Osteoporosis in men: recent progress

Author: Robert A. Adler

Published in: Endocrine | Issue 1/2013

Login to get access

Abstract

As osteoporosis in men has been recognized as an important clinical problem, new information is being accumulated on its scope, pathophysiology, evaluation, and treatment. Fracture risk calculators, such as FRAX, identify a large proportion of the older male population to be at heightened risk for fracture. The classification of osteoporosis into primary and secondary forms, while still useful, is affected by the fact that many men have multiple contributing factors to their fracture risk. The role of sex steroids is being better defined as other risk factors for fracture are delineated. As longevity continues to increase in men and until osteoporotic fracture is truly recognized as a potentially fatal disorder, many men will be undiagnosed and untreated. Two recent studies provide more evidence that treatments which decrease fracture risk in women do the same in men. With the publication of guidelines and increasing strength of evidence for treatment efficacy, it is hoped that more men will be evaluated and treated for this often neglected disorder.
Literature
1.
R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, A.N. Toteston, Incidence and economic burden of osteoporosis-related fracture and subsequent fracture in men and women. JAMA 22, 365–475 (2007)
2.
S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O’Falon, Relationship of serum sex steroids to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86, 3555–3561 (2001)PubMedCrossRef
3.
T.P. van Staa, E.M. Dennison, H.G. Leufkens, C. Cooper, Epidemiology of fractures in England and Wales. Bone 29, 517–522 (2001)PubMedCrossRef
4.
R.B. Hopkins, E. Pullenayegum, R. Goeree, J.D. Adachi, A. Papaioannou, W.E. Leslie, J.E. Tarride, L. Thabane, Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos. Int. 23, 921–927 (2012)PubMedCrossRef
5.
A.C. Feldstein, G. Nichols, E. Orwoll, P.J. Elmer, D.H. Smith, M. Herson, M. Aickin, The near absence of osteoporosis treatment in older men with fractures. Osteoporos. Int. 16, 953–962 (2005)PubMedCrossRef
6.
J.R. Center, D. Bliuc, T.V. Nguyen, J.A. Eisman, Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 24, 387–394 (2007)CrossRef
7.
J.E. Block, H. Stubbs, Hip fracture-associated mortality reconsidered. Calcif. Tissue Int. 61, 84 (1997)PubMedCrossRef
8.
T.P. van Staa, H.G. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf.) 39, 1383–1389 (2000)CrossRef
9.
R.A. Adler, M.C. Hochberg, Glucocorticoid-induced osteoporosis in men. J. Endocrinol. Investig. 34, 481–484 (2011)
10.
G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, R.S. DiPaola, S.L. Yao, Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300, 173–181 (2008)PubMedCrossRef
11.
V.B. Shahinian, Y.F. Kuo, J.L. Freeman, J.S. Goodwin, Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154–164 (2005)PubMedCrossRef
12.
13.
R.A. Adler, Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis 3, 191–200 (2011)PubMedCrossRef
14.
J.A. Kanis, H. Johansson, A. Oden, B. Dawson-Hughes, L.J. Melton III, E.V. McCloskey, The effects of a FRAX revision for the USA. Osteoporos. Int. 21, 35–40 (2010)PubMedCrossRef
15.
N.D. Nguyen, S.A. Frost, J.R. Center, J.A. Eisman, T.V. Nguyen, Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos. Int. 18, 1109–1117 (2008)CrossRef
16.
C.S. Ryan, V.I. Petkov, R.A. Adler, Osteoporosis in men: the value of laboratory testing. Osteoporos. Int. 22, 1845–1853 (2011)PubMedCrossRef
17.
E. Romagnoli, R. Del Fiacco, S. Russo, S. Piemonte, F. Fidanza, F. Colapietro, D. Diacinti, C. Cipriani, S. Minisola, Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J. Rheumatol. 38, 1671–1679 (2011)PubMedCrossRef
18.
L.E. Ryan, S.W. Ing, Idiopathic hypercalciuria and bone health. Curr. Osteoporos. Rep. 10, 286–295 (2012)PubMedCrossRef
19.
P. Vestergaard, L. Rejnmark, L. Mosekilde, Fracture risk associated with the use of morphine and opiates. J. Intern. Med. 260, 76–87 (2006)PubMedCrossRef
20.
S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724–731 (2001)PubMedCrossRef
21.
J.M. Kaufman, A. Vermeulen, The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833–876 (2005)PubMedCrossRef
22.
G. Sartorius, S. Spasevska, A. Idan, L. Turner, E. Forbes, A. Zamojska, C.A. Allan, L.P. Ly, A.J. Conway, R.I. McLachlan, D.J. Handelsman, Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin. Endocrinol. 77, 755–763 (2012)CrossRef
23.
P. Dandona, S. Dhindsa, Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J. Clin. Endocrinol. Metab. 96, 2643–2651 (2011)PubMedCrossRef
24.
K.M. Wiren, A. Chapman Evans, X.W. Zhang, Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J. Endocrinol. 175, 683–694 (2002)PubMedCrossRef
25.
H. Lee, J.S. Finkelstein, M. Miller, S.J. Comeaux, R.I. Cohen, B.Z. Leder, Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J. Clin. Endocrinol. Metab. 91, 1069–1075 (2006)PubMedCrossRef
26.
27.
C.M. Nielson, L.M. Marshall, A.L. Adams, E.S. LeBlanc, P.M. Cawthon, K. Ensrud, E. Barrett-Connor, E.S. Orwoll, Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J. Bone Miner. Res. 26, 496–502 (2011)PubMedCrossRef
28.
L.A. Fitzpatrick, Secondary causes of osteoporosis. Mayo Clin. Proc. 77, 453–468 (2002)PubMed
29.
R.A. Adler, Laboratory testing for secondary osteoporosis evaluation. Clin. Biochem. 45, 894–900 (2012)PubMedCrossRef
30.
G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giiustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011)PubMedCrossRef
31.
C. Torti, G. Mazziotti, P.A. Soldini, E. Foca, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)PubMedCrossRef
32.
T.T. Dam, S. Harrison, H.A. Fink, J. Ramsdell, E. Barrett-Connor, Osteoporotic Fractures in Men (MrOS) Research Group, Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos. Int. 21, 1341–1349 (2010)PubMedCrossRef
33.
G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)PubMedCrossRef
34.
C.E. Lewis, S.K. Ewing, B.C. Taylor, J.M. Shikany, H.A. Fink, K.E. Ensrud, E. Barrett-Connor, S.R. Cummings, E.S. Orwoll, Osteoporotic Fractures in Men (MrOs) Study Research Group, Predictors of non-spine fracture in elderly men: the MrOS Study. J. Bone Miner. Res. 22, 211–219 (2007)PubMedCrossRef
35.
J.A. Cauley, G. El Hajj Fuleihan, A. Arabi, S. Fujiwara, S. Ragi-Eis, A. Calderon, S.B. Chionh, Z. Chen, J.R. Curtis, M.E. Danielson, D.A. Hanley, H. Kroger, A.W. Kung, O. Lesnyak, J. Nieves, W. Pluskiewicz, R. El Rassi, S. Silverman, A.M. Schott, R. Rizzoli, M. Luckey, FRAX Position Conference Members, Official positions for FRAX clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis on FRAX. J. Clin. Densitom. 14, 240–262 (2011)PubMedCrossRef
36.
J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism. Arq. Bras. Endocrinol. Metab. 54, 106–109 (2010)CrossRef
37.
N. Binkley, R.A. Adler, Dual-energy X-ray absorptiometry (DXA) in men, in Osteoporosis in Men, 2nd edn., ed. by E.S. Orwoll, J.P. Bilezikian, D. Vanderschueren (Academic Press, New York, 2010), pp. 525–540CrossRef
38.
T. Isaksen, C.S. Nielsen, S.E. Christensen, P.H. Nissen, L. Heickendorff, L. Mosekilde, Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif. Tissue Int. 89, 285–294 (2011)PubMedCrossRef
39.
D.K. Dhanwal, N. Kochupillai, N. Gupta, C. Cooper, E.M. Dennison, Hypovitaminosis D and bone mineral metabolism and bone density in hyperthyroidism. J. Clin. Densitom. 13, 462–466 (2010)PubMedCrossRef
40.
D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, J.M. Bruder, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87, 3656–3661 (2002)PubMedCrossRef
41.
J.A. Kanis, L.J. Melton III, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137–1141 (1994)PubMedCrossRef
42.
J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22, 2789–2798 (2011)PubMedCrossRef
43.
P.L. Selby, P.L. Davies, J.E. Adams, Do men and women fracture bones at similar bone densities? Osteoporos. Int. 11, 153–157 (2000)PubMedCrossRef
44.
45.
M.G. Donaldson, P.M. Cawthon, L.Y. Lui, J.T. Schousboe, K.E. Ensrud, B.C. Taylor, J.A. Cauley, T.A. Hillier, T.T. Dam, J.R. Curtis, D.M. Black, D.C. Bauer, E.S. Orwoll, S.R. Cummings, Osteoporotic Fractures in Men (MrOS) Study Group, Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation Guidelines. J. Bone Miner. Res. 25, 1506–1511 (2010)PubMedCrossRef
46.
G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef
47.
E.S. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343, 604–610 (2000)PubMedCrossRef
48.
L.H. Klotz, I.Y. McNeill, M. Kebabdjian, L. Zhang, J. Chin, Canadian Urology Research Consortium, A phase 3, double-blind, randomized, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur. Urol. doi:10.​1016/​j.​eururu.​2012.​09.​007
49.
S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24, 719–725 (2009)PubMedCrossRef
50.
P. Taxel, R. Dowsett, L. Richter, P. Fall, A. Klepinger, P. Albertsen, Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int. 106, 1473–1476 (2010)PubMedCrossRef
51.
E.S. Orwoll, N.C. Binkley, E.M. Lewiecki, U. Gruntmanis, M.A. Fries, G. Dasic, Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46, 970–976 (2010)PubMedCrossRef
52.
E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Messenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25, 2239–2250 (2010)PubMedCrossRef
53.
S. Boonen, J.Y. Reginster, J.M. Kaufman, K. Lippuner, J. Zanchetta, B. Langdahl, R. Rizzoli, S. Lipschitz, H.P. Dimai, R. Witvrouw, E. Eriksen, K. Brixen, L. Russo, F. Claessens, P. Papanastasiou, O. Antunez, G. Su, C. Bucci-Rechtweg, J. Hruska, E. Incera, D. Vanderschueren, E. Orwoll, Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 367, 1714–1723 (2012)PubMedCrossRef
54.
K. Sinningen, E. Tsourdi, M. Rauner, T.D. Rachner, C. Hamann, L.C. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42, 52–62 (2012)PubMedCrossRef
55.
E. Orwoll, C.S. Teglbjaerg, B.L. Langdahl, R. Chapurlat, E. Czerwinski, D.L. Kendler, J.Y. Reginster, A. Kivitz, E.M. Lewiecki, P.D. Miller, M.A. Bolognese, M.R. McClung, H.G. Bone, P. Ljimggrem, B. Abrahamsne, U. Gruntmanis, Y.C. Yang, R.B. Wagman, S. Siddhanti, A. Grauer, J.W. Hall, S. Boonen, A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161–3169 (2012)PubMedCrossRef
56.
M.R. Smith, B. Egerdie, N.H. Toriz, R. Feldman, T.L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab HALT Prostate Cancer Study Group, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009)PubMedCrossRef
57.
N.E. Cusano, A.G. Costa, B.C. Silva, J.P. Bilezikian, Therapy of osteoporosis in men with teriparatide. J. Osteoporos. 2011, 463675 (2011). doi:10.​4061/​2011/​463675
58.
J.M. Kaufman, E. Orwoll, S. Goemaere, J. San Martin, A. Hossain, G.P. Dalsky, R. Linsday, B.H. Mitlak, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510–516 (2005)PubMedCrossRef
59.
J.D. Ringe, A. Dorst, P. Farahmand, Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 60, 267–272 (2010)PubMed
60.
H.M. Behre, S. Kliesch, E. Leifke, T.M. Link, E. Nieschlag, Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 2386–2390 (1997)
61.
J.K. Amory, N.B. Watts, K.A. Easley, P.R. Sutton, B.D. Anawalt, A.M. Matsumoto, W.J. Bremer, J.L. Tenover, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503–510 (2004)PubMedCrossRef
62.
P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, J.H. Holmes, A. Dlewati, J. Staley, J. Santanna, S.C. Kapoor, M.F. Attie, J.G. Haddad Jr., B.L. Strom, Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84, 1966–1972 (1999)PubMedCrossRef
63.
N.B. Watts, R.A. Adler, J.P. Bilezikian, M.T. Drake, R. Eastell, E.S. Orwoll, J.S. Finkelstein, Osteoporosis in men: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 97, 1802–1822 (2012)PubMedCrossRef
64.
J. Compston, Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos. Int. 22, 2951–2961 (2011)PubMedCrossRef
65.
S.V. Reddy, S.K. Gupta, Atypical femoral shaft fractures in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singap. Med. J. 53, e52–e54 (2012)
66.
N.B. Watts, D.L. Diab, Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555–1565 (2010)PubMedCrossRef
Metadata
Title
Osteoporosis in men: recent progress
Author
Robert A. Adler
Publication date
01-08-2013
Publisher
Springer US
Published in
Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-9880-7

Other articles of this Issue 1/2013

Endocrine 1/2013 Go to the issue

Original Article

Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women

Original Article

Fructose intake during pregnancy up-regulates the expression of maternal and fetal hepatic sterol regulatory element-binding protein-1c in rats

Review

Mifepristone: is there a place in the treatment of Cushing’s disease?

Original Article

Is autoimmune thyroiditis a risk factor for early atherosclerosis in premenopausal women even if in euthyroid status?

Letter to the Editor

Treatment refractory hypothyroidism as a result of excessive donation of plasma

Erratum

Erratum to: The aldosterone to renin ratio in the evaluation of patients with incidentally detected adrenal masses
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits